Exparel 133 MG/10 ML vial 10ML
Ended Awarded
- Contract number
- SPE2DB26FQAAX
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,437
Award facts
- Contract value 100% obligated
- $2,436.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,436.88 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 mL vials. The contract is a firm fixed-price delivery order with an ultimate completion date of December 2, 2025, and was issued without a set-aside designation, indicating the awardee competed in an unrestricted procurement environment. DMS Pharmaceutical Group Inc. is the prime contractor on this award with no identified subcontractors.
This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA known as the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $499.9 billion initiative awarded on November 13, 2025, with a completion date of December 31, 2036. The PPV-G GEN V represents part of the DLA's $30.3 billion pharmaceutical supply strategy designed to provide Department of Defense military healthcare facilities worldwide with a comprehensive range of branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables. DMS Pharmaceutical Group's established performance across numerous delivery orders for specialty pharmaceuticals and surgical products demonstrates its capability to serve as a critical pharmaceutical supplier supporting DoD healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB26FQAAX?
SPE2DB26FQAAX was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 7, 2025.
How much is contract SPE2DB26FQAAX worth?
The government has obligated $2,437 on SPE2DB26FQAAX.
Is contract SPE2DB26FQAAX an order under another contract?
Yes. SPE2DB26FQAAX is a delivery order under SPE2DB25D9305, an indefinite delivery contract.
Was contract SPE2DB26FQAAX competed?
The extent of competition for SPE2DB26FQAAX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award